Why we should use mild stimulation in egg donation
By Guido Pennings,
BioNews
| 11. 30. 2020
There are two strong ethical reasons to avoid harm to egg donors: a duty to minimise harm and the proportionality rule. The general duty to minimise harm applies to all medical interventions but it is even more relevant for donors because they are submitting to the intervention for the benefit of others. Most forms of body material donation will carry with them some harm. This duty does not make that unacceptable but implies that harm is only acceptable when it is unavoidable, and this duty cannot be bypassed by asking the donor for consent. The informed consent form is not a safe conduct for high risks.
Whenever you mention ovarian hyperstimulation syndrome (OHSS) to a clinician, they will reply that it was indeed a serious problem in the past but that it is under control now. The current stimulation protocols bring the risk of OHSS down to zero. However, one wonders how the statistics can be explained as data from the European IVF-Monitoring Consortium show that severe OHSS has not disappeared. Moreover, the American Society for Reproductive Medicine recently calculated that...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...